Measuring ageing

Biotein is building a low-cost saliva test to measure protein markers of age-related cellular damage.

Deep Longevity provides AI-powered aging clocks and SaaS platforms for biological age prediction and personalized health insights.

Edifice Health provides inflammatory health monitoring tests to help patients and clinicians manage systemic chronic inflammation.

Generation Lab offers an epigenetic SystemAge test with personalized insights across 460 biomarkers and 21 organs and systems.

Life Length measures aging and disease biology using telomere, telomerase, oxidative stress, NAD+, and single-cell biomarker diagnostics.

MyAgingTests provides epigenetic biological age testing and evidence-backed tools for longevity interventions.

Sapere Bio provides biomarker testing for longevity, immune resilience, cellular senescence, and athletic performance.

Tally Health provides epigenetic age testing, longevity supplements, and personalized insights designed to improve healthspan and longevity.

Vero uses proteomics and machine learning to measure organ-level biological age from a single blood draw.

CHANGS is a newly announced 2025 Chulalongkorn University-BGI collaboration in Thailand focused on healthy aging, using omics and AI-based bioinformatics to analyze elderly health, collect volunteer samples and clinical data, and reportedly build outputs such as multi-omic aging measures and organ-aging models. The evidence supports that the project exists and has institutional backing, but not that it has yet produced validated biomarkers, intervention results, or clinical utility.

Japan Longevity Consortium is a Japan-based academic consortium led from Juntendo University that is promoting a biomarker-guided, multi-component “Scientific Zen” healthspan program combining washoku-style diet, mild fasting, exercise, yoga/breathing, TEAS, far-infrared therapy, supplementation, and gut-focused management to improve cognition, immune function, and muscle function. The strongest signals are a senior university team, XPRIZE Healthspan Top 40 semifinalist status, and self-reported preliminary observational findings on epigenetic-age and autonomic outcomes; the main constraint is that the core efficacy claims are currently presented mostly on the consortium’s own site or institutional announcements, with limited methodological detail and no clearly linked peer-reviewed validation of the full program.